Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Polyrizon launches preclinical studies for intranasal naloxone
Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.
Nasdaq6d
Polyrizon Ltd. Initiates Preclinical Studies for Intranasal Naloxone to Enhance Opioid Overdose Treatment
has started preclinical studies for an intranasal formulation of Naloxone, intended to treat opioid overdoses. Collaborating with Professor Fabio Sonvico from the University of Parma, the studies ...
Yahoo Finance6d
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
These preclinical studies mark a step forward in evaluating Polyrizon's Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly ...
Investing6d
Polyrizon advances naloxone intranasal delivery studies
Naloxone has been a cornerstone in the fight against the opioid epidemic, which has seen a surge in fatalities due to synthetic opioids like fentanyl. The intranasal delivery method of Naloxone ...
Investing6d
Polyrizon advances naloxone intranasal delivery studies
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage with a market capitalization of $2.95 million, is progressing in its preclinical studies for an intranasal ...